# RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery

> **NCT00168805** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 2101 (actual)

## Conditions studied

- Arthroplasty, Replacement, Knee
- Thromboembolism

## Interventions

- **DRUG:** enoxaparin
- **DRUG:** dabigatran etexilate
- **DRUG:** dabigatran etexilate

## Key facts

- **NCT ID:** NCT00168805
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2006-05
- **Final completion:** —
- **Target enrollment:** 2101 (ACTUAL)
- **Last updated:** 2014-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00168805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00168805, "RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00168805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*